---
title: "Novacyt S.A. (NCYT.L) Director/PDMR Shareholding"
publisher: "Share Talk"
author: "sharetalk"
published: "2020-11-12T08:28:22+00:00"
modified: "2020-11-12T08:28:22+00:00"
date: 2020-11-12
canonical: "https://www.share-talk.com/novacyt-s-a-ncyt-l-director-pdmr-shareholding/"
category: "Healthcare"
categories: ["Healthcare"]
tags: ["development", "diagnostic", "diagnostics", "Graham Mullis", "haematology", "IT-IS", "IT-IS International Ltd", "Lab21", "Lab21 Products", "microbiology", "molecular", "NCYT", "Novacyt S.A.", "Primerdesign", "product", "Roderic Fuerst", "serology", "serology markets", "vitro"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Novacyt S.A. (NCYT.L) Director/PDMR Shareholding

**Published:** November 12, 2020
**Author:** sharetalk
**Categories:** Healthcare
**Tags:** development, diagnostic, diagnostics, Graham Mullis, haematology, IT-IS, IT-IS International Ltd, Lab21, Lab21 Products, microbiology, molecular, NCYT, Novacyt S.A., Primerdesign, product, Roderic Fuerst, serology, serology markets, vitro
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

Paris, France and Camberley, UK – 12 November 2020 – **Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT)**, an international specialist in clinical diagnostics, announces that it has been notified that, on 11 November 2020.

**Graham Mullis, Chief Executive of the Company**, acquired 60,875 ordinary shares of €1/15 each in the Company at a price of £8.17 per share.  The resultant beneficial shareholding of Mr Mullis is 122,506 ordinary shares representing 0.17% of the Company’s issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

|   |   |   |   |
| --- | --- | --- | --- |
| 1. | Details of the person discharging managerial responsibilities / person closely associated |  |  |
| a) | Name |   Graham Mullis, Chief Executive Officer   |  |
| 2. | Reason for the Notification |  |  |
| a) | Position/status | See 1(a) – classified as a PDMR of the Company   |  |
| b) | Initial notification/ Amendment | Initial Notification   |  |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |  |  |
| a) | Name | Novacyt S.A. |  |
| b) | LEI | 213800BWAC2BF295EG28 |  |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |  |  |
| a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each   |  |
|  | Identification code | FR0010397232 |  |
| b) | Nature of the transaction | Acquisition of Ordinary Shares   |  |
| c) | Price(s) and volume(s) |   Price | Volume |
| £8.17 | 60,875 |  |  |

d)

Aggregated information:

· Aggregated volume

· Price

 

|   |   |
| --- | --- |
| Price | Volume |
| £8.17 | 60,875 |

 

 

e)

Date of the transaction

 

11 November 2020

f)

Place of the transaction

London Stock Exchange, AIM

**Contacts**

**Novacyt SA**

**Graham Mullis, Chief Executive Officer**

**Anthony Dyer, Chief Financial Officer**

**+44 (0)1276 600081**

---

**Original URL:** https://www.share-talk.com/novacyt-s-a-ncyt-l-director-pdmr-shareholding/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*